Similarly, the DNA damage repair associated lncRNA risk model revealed that low-risk patients exhibited higher tumor mutational burden (TMB) and increased cytotoxic T lymphocyte (CTL) activity, resulting in improved clinical outcomes following anti-PD-L1 treatment [70]. Here, CD274 is linked to neoplasm.